PM David Cameron opens e-Therapeutics’ drug discovery centre

Network Pharmacology Centre will search for novel treatments for cancer and CNS diseases

UK drug discovery and development firm e-Therapeutics has opened a new drug discovery centre at Long Hanborough, near Oxford.

The Network Pharmacology Centre will focus on searching for novel treatments for cancer and degenerative diseases of the nervous system.

UK Prime Minister David Cameron officially opened the centre.

He said: ‘e-Therapeutics is a fascinating and innovative business in my constituency. Their use of pioneering science has the potential to deliver great results and I very much hope that their treatments are successful.’

Professor Malcolm Young, founder and chief executive of e-Therapeutics, added: ‘We are delighted to have the Prime Minister open our new drug discovery centre near Oxford, which is a world centre of excellence in the science that underpins our business.’

The new centre will spearhead e-Therapeutics’ pioneering work in network pharmacology, which involves application of network analysis to determine the set of proteins most critical in any disease, and then chemical biology to identify molecules capable of targeting that set of proteins.

The firm says by addressing the true complexity of disease and by seeking to harness the ability of drugs to influence many different proteins, network pharmacology differs from conventional drug discovery approaches, which have generally been based on highly specific targeting of a single protein.

During 2012, e-Therapeutics plans to advance four drugs derived from network pharmacology research into clinical trials. These include potential treatments for cancer, major depressive disorder and resistant bacterial infections.

The firm’s headquarters are in Newcastle-upon-Tyne.

You may also like

Ingredients

e-therapeutics launches anti-viral drug discovery initiative for COVID-19

UK-based e-therapeutics discusses the moral responsibility of business and reaches out for aid with a network-driven drug discovery platform to help the current pandemic
Research & Development

Could machine learning present a paradigm shift in drug discovery?

Angharad Baldwin catches up with Dr Raymond Barlow, CEO at e-therapeutics, about what network-driven drug discovery can offer the pharmaceutical industry in its pursuit of new medicines
Research & Development

Collaboration to enhance and extend AI technology capabilities

e-Therapeutics, a company pioneering the use of network-driven drug discovery (NDD) to create new and better drugs, announced agreements with Intellegens and Biorelate to develop artificial intelligence (AI) technology capabilities
Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing

L.B. Bohle hosts successful continuous manufacturing workshop in Brazil

Focus on continuous wet granulation and drying for research, development and small-scale production
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Research & Development

Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption

A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Subscribe now